within Pharmacolibrary.Drugs.ATC.C;

model C10BA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.9166666666666666,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Simvastatin and fenofibrate is a fixed-dose combination medication used to treat mixed dyslipidemia and hypercholesterolemia by lowering LDL cholesterol, triglycerides, and raising HDL cholesterol. Simvastatin is a statin that inhibits HMG-CoA reductase, while fenofibrate is a fibric acid derivative that acts on PPAR-alpha. This combination is approved and used in clinical practice for patients at risk of cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameter estimates are available for the fixed combination of simvastatin and fenofibrate as C10BA04. Monographs exist for the single agents (simvastatin and fenofibrate separately), but no comprehensive PK model is documented for the fixed combination in healthy volunteers or patients as of 2024.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Penn, R, et al., &amp; Rains, KT (2006). An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. <i>Clinical therapeutics</i> 28(1) 45–54. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2005.12.004&quot;>10.1016/j.clinthera.2005.12.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16490579/&quot;>https://pubmed.ncbi.nlm.nih.gov/16490579</a></p></li><li><p>Miller, DB, &amp; Spence, JD (1998). Clinical pharmacokinetics of fibric acid derivatives (fibrates). <i>Clinical pharmacokinetics</i> 34(2) 155–162. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199834020-00003&quot;>10.2165/00003088-199834020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9515185/&quot;>https://pubmed.ncbi.nlm.nih.gov/9515185</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C10BA04;
